Sunday, November 8, 2026

GBP/EUR Bearish Momentum With A 2% Drop In The Last 21 Sessions

ViaNews Editorial Team

August 14, 2024

GBP/EUR Bearish Momentum With A 2% Drop In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 2.09% for the last 21 sessions. At 07:10 EST on Wednesday, 14 August, GBP/EUR (GBPEUR) is $1.17.

GBP/EUR's yearly highs and lows, it's 2.148% up from its 52-week low and 2.306% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.15%, a negative 0.07%, and a positive 0.17%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.18% (last week), 0.22% (last month), and 0.17% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy trims part of modest gains amid geopolitical risks, up a little around 146.75-80 area. According to FXStreet on Monday, 12 August, "Apart from this, a generally positive tone around the equity markets dents the JPY's relative safe-haven status, which, along with a modest US Dollar (USD) uptick, contributes to the bid tone surrounding the USD/JPY pair. ", "This, in turn, contributes to keeping a lid on the USD/JPY pair amid relatively thin liquidity on the back of a holiday in Japan and absent relevant market-moving economic data."
  • According to FXStreet on Monday, 12 August, "This means that while it was possible to earn almost 5% p.a. on a USD/JPY carry trade, the market expected the spot rate to fluctuate by an average of 9% over the course of the next 12 months.", "The fact that exchange rate movements appear excessive to the layperson, that it may seem implausible, for example, that a 25 basis point increase in JPY interest rates justifies a USD/JPY slide by more than 10 big figures, is of course due to a dynamic that is quite well understood by economists. "
  • Usd/jpy price forecast: rises, yet struggles at 148.00. According to FXStreet on Monday, 12 August, "The Japanese Yen fails to gain traction late in the North American session versus the Greenback as the USD/JPY rises from last Friday's daily low of 146.62 and trades at 147.28, up by 0.47%.", "The USD/JPY is downward biased despite the uptick that saw the pair clear the 148.00 figure and hit a six-day high at 148.22 before reversing its course and tumbling below the Tenkan-Sen at 147.79."
  • Usd/jpy: taking a breather? – rabobank. According to FXStreet on Tuesday, 13 August, "In our view this will likely start with a recovery in the value of the USD over the coming days, though we expect that USD/JPY can still trend lower on a 3-to-6-month view'."
  • According to FXStreet on Tuesday, 13 August, "The USD/JPY pair receives support as the pressure on the US Dollar eases due to decreased expectations for a 50 basis point interest rate cut by the US Federal Reserve (Fed) in September. ", "On the upside, the USD/JPY pair could test the immediate barrier at the nine-day EMA around the 147.72 level. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com